ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

Summary

24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance. If the subject does not reach the EAS LDL-C treatment goal at week 12, rosuvastatin will be titrated from 10mg to 20mg.

Timeline

Start

2002-02

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “study cancelled prior to FSI”

Drugs

Indications